Drug Profile
EV 029104
Alternative Names: EV029104Latest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator Evec
- Class Antibacterials; Monoclonal antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Clostridium difficile infections
Most Recent Events
- 05 Sep 2023 Preclinical development is ongoing in Japan for Clostridium-difficile-infections (Prevention) in Japan
- 05 Sep 2023 Preclinical development is ongoing in Japan for Clostridium-difficile-infections
- 28 Jul 2018 No development reported - Preclinical for Clostridium difficile infections (Prevention) in Japan (Parenteral)